{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T21:51:43Z","timestamp":1783720303179,"version":"3.55.0"},"reference-count":30,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Localization of subcentimeter ground glass opacities during minimally invasive thoracoscopic lung cancer resections is a significant challenge in thoracic oncology. Intraoperative molecular imaging has emerged as a potential solution, but the availability of suitable fluorescence agents is a limiting factor.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate the suitability of SGM-101, a carcinoembryonic antigen\u2013related cell adhesion molecule type 5 (CEACAM5) receptor\u2013targeted near-infrared fluorochrome, for molecular imaging\u2013guided lung cancer resections, because glycoprotein is expressed in more than 80% of adenocarcinomas.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>For this nonrandomized, proof-of-principal, phase 1 controlled trial, patients were divided into 2 groups between August 1, 2020, and January 31, 2022. Patients with known CEACAM5-positive gastrointestinal tumors suggestive of lung metastasis were selected as proof-of-principle positive controls. The investigative group included patients with lung nodules suggestive of primary lung malignant neoplasms. Patients 18 years or older without significant comorbidities that precluded surgical exploration with suspicious pulmonary nodules requiring surgical biopsy were included in the study.<\/jats:p><\/jats:sec>Interventions<\/jats:title>SGM-101 (10 mg) was infused up to 5 days before index operation, and pulmonary nodules were imaged using a near-infrared camera system with a dedicated thoracoscope.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>SGM-101 localization to pulmonary nodules and its correlation with CEACAM5 glycoprotein expression by the tumor as quantified by tumor and normal pulmonary parenchymal fluorescence.<\/jats:p><\/jats:sec>Results<\/jats:title>Ten patients (5 per group; 5 male and 5 female; median [IQR] age, 66 [58-69] years) with 14 total lesions (median [range] lesion size, 0.91 [0.90-2.00] cm) were enrolled in the study. In the control group of 4 patients (1 patient did not undergo surgical resection because of abnormal preoperative cardiac clearance findings that were not deemed related to SGM-101 infusion), the mean (SD) lesion size was 1.33 (0.48) cm, 2 patients had elevated serum CEA markers, and 2 patients had normal serum CEA levels. Of the 4 patients who underwent surgical intervention, those with 2+ and 3+ tissue CEACAM5 expression had excellent tumor fluorescence, with a mean (SD) tumor to background ratio of 3.11 (0.45). In the patient cohort, the mean (SD) lesion size was 0.68 (0.22) cm, and no elevations in serum CEA levels were found. Lack of SGM-101 fluorescence was associated with benign lesions and with lack of CEACAM5 staining.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This in-human proof-of-principle nonrandomized controlled trial demonstrated SGM-101 localization to CEACAM5-positive tumors with the detection of real-time near-infrared fluorescence in situ, ex vivo, and by immunofluorescence microscopy. These findings suggest that SGM-101 is a safe, receptor-specific, and feasible intraoperative molecular imaging fluorochrome that should be further evaluated in randomized clinical trials.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT04315467<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.52885","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T16:00:55Z","timestamp":1674835255000},"page":"e2252885","source":"Crossref","is-referenced-by-count":18,"title":["Carcinoembryonic Antigen\u2013Related Cell Adhesion Molecule Type 5 Receptor\u2013Targeted Fluorescent Intraoperative Molecular Imaging Tracer for Lung Cancer"],"prefix":"10.1001","volume":"6","author":[{"given":"Feredun","family":"Azari","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben P. J.","family":"Meijer","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research, Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory T.","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hanna","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal","family":"Nadeem","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azra","family":"Din","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"P\u00e8legrin","sequence":"additional","affiliation":[{"name":"SurgiMab, Montpellier, France"},{"name":"Institute of Cancer Research of Montpellier, University of Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9r\u00e9nice","family":"Framery","sequence":"additional","affiliation":[{"name":"SurgiMab, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Cailler","sequence":"additional","affiliation":[{"name":"SurgiMab, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil T.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kucharczuk","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda W.","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, University of Virginia School of Medicine, Charlottesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander L.","family":"Vahrmeijer","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research, Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Singhal","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,1,27]]},"reference":[{"key":"zoi221499r1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-24223-1","article-title":"Lung cancer statistics.","volume":"893","author":"Torre","year":"2016","journal-title":"Adv Exp Med Biol"},{"issue":"10","key":"zoi221499r2","doi-asserted-by":"publisher","first-page":"E1317","DOI":"10.21037\/jtd","article-title":"Measures of outcome in lung cancer screening: maximising the benefits.","volume":"8","author":"Young","year":"2016","journal-title":"J Thorac Dis"},{"key":"zoi221499r3","doi-asserted-by":"publisher","first-page":"S404","DOI":"10.21037\/jtd","article-title":"Immunotherapy in surgically resectable non-small cell lung cancer.","volume":"10","author":"Owen","year":"2018","journal-title":"J Thorac Dis"},{"issue":"15","key":"zoi221499r4","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.3390\/cancers13153711","article-title":"The role of surgery in lung cancer treatment: present indications and future perspectives-state of the art.","volume":"13","author":"Montagne","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"10066","key":"zoi221499r5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","article-title":"Lung cancer: current therapies and new targeted treatments.","volume":"389","author":"Hirsch","year":"2017","journal-title":"Lancet"},{"issue":"12","key":"zoi221499r6","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/j.jtho.2017.08.015","article-title":"Prognostic impact of margin distance and tumor spread through air spaces in limited resection for primary lung cancer.","volume":"12","author":"Masai","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"4","key":"zoi221499r7","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.soc.2020.06.006","article-title":"Intraoperative detection and assessment of lung nodules.","volume":"29","author":"Azari","year":"2020","journal-title":"Surg Oncol Clin N Am"},{"issue":"5","key":"zoi221499r8","doi-asserted-by":"publisher","DOI":"10.1117\/1.JBO.26.5.050901","article-title":"Intraoperative molecular imaging clinical trials: a review of 2020 conference proceedings.","volume":"26","author":"Azari","year":"2021","journal-title":"J Biomed Opt"},{"issue":"11","key":"zoi221499r9","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1001\/jamasurg.2021.3757","article-title":"Targeted intraoperative molecular imaging for localizing nonpalpable tumors and quantifying resection margin distances.","volume":"156","author":"Kennedy","year":"2021","journal-title":"JAMA Surg"},{"issue":"3","key":"zoi221499r10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11060-019-03098-y","article-title":"5-ALA and FDA approval for glioma surgery.","volume":"141","author":"Hadjipanayis","year":"2019","journal-title":"J Neurooncol"},{"issue":"5","key":"zoi221499r11","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1097\/XCS.0000000000000132","article-title":"Impact of intraoperative molecular imaging after fluorescent-guided pulmonary metastasectomy for sarcoma.","volume":"234","author":"Azari","year":"2022","journal-title":"J Am Coll Surg"},{"issue":"12","key":"zoi221499r12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1117\/1.JBO.24.12.120901","article-title":"Review of clinical trials in intraoperative molecular imaging during cancer surgery.","volume":"24","author":"Lee","year":"2019","journal-title":"J Biomed Opt"},{"issue":"1","key":"zoi221499r13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ygyno.2019.07.010","article-title":"A phase II, multicenter, open-label trial of OTL38 injection for the intra-operative imaging of folate receptor-alpha positive ovarian cancer.","volume":"155","author":"Randall","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"7","key":"zoi221499r14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182034","article-title":"The second window ICG technique demonstrates a broad plateau period for near infrared fluorescence tumor contrast in glioblastoma.","volume":"12","author":"Zeh","year":"2017","journal-title":"PLoS One"},{"key":"zoi221499r15","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-021-01699-6","article-title":"Effects of light-absorbing carbons in intraoperative molecular imaging-guided lung cancer resections.","author":"Azari","year":"2022","journal-title":"Mol Imaging Biol"},{"key":"zoi221499r16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1471-2407-7-2","article-title":"Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers.","volume":"7","author":"Blumenthal","year":"2007","journal-title":"BMC Cancer"},{"issue":"1","key":"zoi221499r17","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1186\/s12885-017-3474-3","article-title":"Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations.","volume":"17","author":"Gao","year":"2017","journal-title":"BMC Cancer"},{"issue":"1","key":"zoi221499r18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1465-9921-14-85","article-title":"Carcinoembryonic antigen (CEA)-related cell adhesion molecules are co-expressed in the human lung and their expression can be modulated in bronchial epithelial cells by non-typable Haemophilus influenzae, Moraxella catarrhalis, TLR3, and type I and II interferons.","volume":"14","author":"Klaile","year":"2013","journal-title":"Respir Res"},{"issue":"7","key":"zoi221499r19","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1097\/JTO.0b013e31828f696b","article-title":"Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.","volume":"8","author":"Muley","year":"2013","journal-title":"J Thorac Oncol"},{"key":"zoi221499r20","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/1471-2407-13-254","article-title":"Usefulness of serum carcinoembryonic antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: a prospective cohort study.","volume":"13","author":"Arrieta","year":"2013","journal-title":"BMC Cancer"},{"issue":"3","key":"zoi221499r21","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1245\/s10434-020-09069-2","article-title":"Dose-finding study of a CEA-targeting agent, SGM-101, for intraoperative fluorescence imaging of colorectal cancer.","volume":"28","author":"de Valk","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"zoi221499r22","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12885-020-6524-1","article-title":"The combination of CTCs and CEA can help guide the management of patients with SPNs suspected of being lung cancer.","volume":"20","author":"Zheng","year":"2020","journal-title":"BMC Cancer"},{"issue":"1","key":"zoi221499r23","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s00330-016-4352-0","article-title":"Evaluation of carcinoembryonic antigen (CEA) density as a prognostic factor for percutaneous ablation of pulmonary colorectal metastases.","volume":"27","author":"Huo","year":"2017","journal-title":"Eur Radiol"},{"issue":"3","key":"zoi221499r24","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S2468-1253(17)30395-3","article-title":"Safety and effectiveness of SGM-101, a fluorescent antibody targeting carcinoembryonic antigen, for intraoperative detection of colorectal cancer: a dose-escalation pilot study.","volume":"3","author":"Boogerd","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"zoi221499r25","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.suronc.2017.03.002","article-title":"SGM-101: An innovative near-infrared dye-antibody conjugate that targets CEA for fluorescence-guided surgery.","volume":"26","author":"Gutowski","year":"2017","journal-title":"Surg Oncol"},{"issue":"11","key":"zoi221499r26","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1245\/s10434-018-6655-7","article-title":"Image-guided surgery in patients with pancreatic cancer: first results of a clinical trial using SGM-101, a novel carcinoembryonic antigen-targeting, near-infrared fluorescent agent.","volume":"25","author":"Hoogstins","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"zoi221499r27","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.lungcan.2018.05.012","article-title":"Screening values of carcinoembryonic antigen and cytokeratin 19 fragment for lung cancer in combination with low-dose computed tomography in high-risk populations: Initial and 2-year screening outcomes.","volume":"122","author":"Triphuridet","year":"2018","journal-title":"Lung Cancer"},{"issue":"1","key":"zoi221499r28","doi-asserted-by":"publisher","first-page":"19044","DOI":"10.1038\/s41598-021-98513-8","article-title":"Serum carcinoembryonic antigen elevation in benign lung diseases.","volume":"11","author":"Yang","year":"2021","journal-title":"Sci Rep"},{"issue":"5","key":"zoi221499r29","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"zoi221499r30","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2022.05.019","article-title":"Glycoprotein receptor CEACAM5-targeted intraoperative molecular imaging tracer in non-small cell lung cancer.","author":"Azari","year":"2022","journal-title":"Ann Thorac Surg"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2800860\/azari_2023_oi_221499_1692375066.46669.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T15:01:17Z","timestamp":1692889277000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2800860"}},"subtitle":["A Nonrandomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2023,1,27]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.52885","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,27]]}}}